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Abstract
Introduction: Standard pre-operative diagnosis of nodular goitre is not always conclusive. The decision about nodular goitre surgery is 
increasingly based on molecular methods. 
The aim of the study was to determine BRAF T1799A mutation and KRas proto-oncogene mutation, and the analysis of RASSF1A promoter 
methylation level in cytological material obtained from FNAB specimens of thyroid nodules. 
Material and methods: The study population consisted of 85 women and 12 men. The study material was genomic DNA isolated from 
peripheral blood and thyroid bioptates. Pyrosequencing was used for the evaluation of RASSF1 methylation level. KRas mutation was 
investigated with Sanger sequencing. BRAF mutation was analysed by standard methods of real-time amplification detection (real-time 
PCR) with the use of specific starters surrounding the mutated site.
Results: A significant positive correlation was demonstrated between mean methylation of four CpG islands of RASSF1A gene and thyroid 
tumour volume and its largest diameter (p < 0.05). KRas mutation was not detected in any of the 97 patients. In 7/85 subjects (8.2%) BRAF 
mutation was observed. In 6/7 patients with BRAF mutation, FNAB of thyroid nodules confirmed a benign nature of the lesions; the material 
was non-diagnostic in one patient, and papillary thyroid cancer was diagnosed on the basis of postoperative histopathology assessment. 
Conclusions: The results of genetic tests reported in our study indicate that the presence of BRAF mutation or higher RASSF1A methyla-
tion levels in FNAB cytology specimens of benign lesions may be useful in the assessment of oncological risk, while the evaluation of 
KRas proto-oncogene mutation is not a valuable test in pre-operative diagnosis of nodular goitre. (Endokrynol Pol 2015; 66 (5): 384–393)
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Streszczenie
Wstęp: Na podstawie standardowej przedoperacyjnej diagnostyki wola guzkowego nie zawsze uzyskuje się jednoznaczne rozpoznanie. 
Coraz częściej w kwalifikacji wola guzkowego do zabiegu operacyjnego wykorzystywane są metody badań molekularnych. 
Celem pracy było oznaczenie mutacji T1799A genu BRAF i mutacji protoonkogenu KRas oraz analiza stopnia metylacji promotora genu 
RASSF1A w materiale komórkowym uzyskanym z guzków tarczycy na drodze biopsji aspiracyjnej cienkoigłowej. 
Materiały i metody: Badaniami objęto 85 kobiet i 12 mężczyzn. Materiał do badań stanowił genomowy DNA wyizolowany z krwi ob-
wodowej pacjentów oraz z bioptatów tarczycy. Do oceny stopnia metylacji genu RASSF1 wykorzystano metodę pirosekwencjonowania. 
Mutacje genu KRas badano metodą sekwencjonowania Sangera. Do oznaczania mutacji BRAF użyto standardowej metodologii detekcji 
amplifikacji w czasie rzeczywistym (real-time PCR) z zastosowaniem specyficznych starterów otaczających miejsce zmutowane.
Wyniki: Wykazano, że średnia metylacji czterech wysp CpG w genie RASSF1A znamiennie, dodatnio koreluje z objętością guza tarczycy 
i największym wymiarem guza (p < 0,05). U żadnej z 97 osób nie stwierdzono mutacji Kras. U 7/85 badanych (8,2%) stwierdzono obecność 
mutacji genu BRAF. U 6/7 osób z obecnością mutacji BRAF, BAC guzków tarczycy wykazała łagodny charakter tych zmian, u jednej osoby otrzy-
mano materiał niediagnostyczny, a na podstawie pooperacyjnego badania histopatologicznego rozpoznano raka brodawkowatego tarczycy. 
Wnioski: Otrzymane wyniki badań genetycznych wskazują, że obecność mutacji genu BRAF lub wyższego odsetka metylacji genu 
RASSF1A w materiale cytologicznym z biopsji aspiracyjnej cienkoigłowej zmiany cytologicznie łagodnej może mieć znaczenie w ocenie 
zagrożenia onkologicznego, podczas gdy ocena mutacji protonkogenu KRas nie jest przydatna w diagnostyce przedoperacyjnej wola 
guzkowego. (Endokrynol Pol 2015; 66 (5): 384–393)
Słowa kluczowe: wole guzkowe; biopsja aspiracyjna cienkoigłowa; mutacja genu BRAFV600E; mutacja Kras; metylacja RASSF1A
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 — Laboratory tests: serum levels of TSH, fT4, fT3, anti-
thyroglobulin, and antimicrosomal antibodies. TSH 
(n 0.27–4.2 uIU/mL), fT4 (n 0.9–1.8 ng/dL), and fT3 
(n 2.00-4.4 pg/dL) levels were determined with elec-
trochemiluminescence using commercial kits, while 
antithyroglobulin and antimicrosomal antibody 
levels were measured with microparticle enzyme 
immunoassay (MEIA) using commercial kits.
 — A thyroid ultrasound was performed with an ALO-
KA ultrasound system and a 5–12 MHz linear 
transducer. All thyroid ultrasound investigations 
were performed by an experienced endocrinologist. 
 — US-guided fine-needle aspiration biopsy of a focal 
lesion in the thyroid gland selected on the basis of 
its US characteristics.
 — FNAB cytology. Cytology assessment was based on 
international Bethesda System with six diagnostic 
categories for reporting thyroid cytopathology in 
FNAB samples of thyroid tumour.
 — FNAB and peripheral blood samples were prese-
rved for genetic testing including the assessment 
of RASSF1A gene methylation and the detection of 
mutations in BRAF (T1799A) and KRas genes. These 
tests were performed in patients treated at the Endo-
crine Outpatient Clinic located at our hospital. The 
subjects included in the study gave their informed 
consent to take part in this scientific research. The 
study was approved by the Ethics Committee at 
Pomeranian Medical University in Szczecin.
The study material consisted of genomic DNA 
isolated from patients’ peripheral blood and thyroid 
bioptates. Peripheral blood samples were collected 
into ethylenediaminetetraacetic acid (EDTA) test tubes 
and stored at –20˚C until DNA isolation. The samples 
of the material obtained from thyroid biopsy were 
collected into RNA later buffer (Ambion) and stored 
at –80˚C until DNA isolation. QIAamp DNA Blood 
Mini Kit (QIAGEN) was used for DNA isolation from 
blood, while DNA was isolated from bioptates with 
AutoMate Express DNA Extraction System (Applied 
Biosystems) using a PrepFiler Express Forensic DNA 
Extraction Kit (Applied Biosystems). Then, DNA isolate 
levels were measured with a PICODROP (Picodrop) 
UV/Vis spectrophotometer. All DNA samples obtained 
from bioptates were modified with sodium bisulphate 
— Epitect Bisulfite Kit (QIAGEN). 
Pyrosequencing was used for the assessment  
of RASSF1 promoter methylation.  
Preparation of biotinylated PCR product 
RASSF1 fragment (chr3:50374236-50374409) containing 
four CpG islands was analysed. Nucleotide sequence of 
analysed RASSF1 fragment: TCGAACGCGGAAATCGA 
(CpG islands have been underlined). Having optimised 
This work was supported by a grant from the Polish Minis-
try of Science and Higher Education (no. N N402 466739). 
Introduction
Nodular goitre is the most common pathology of the 
thyroid gland. Palpable thyroid nodules are found in 
4–7% adults and are more frequent in women than in 
men [1]. The ultrasonography findings showed that the 
thyroid nodules are visualised in nearly 60% of clini-
cally normal thyroid glands. In the majority of cases, 
these nodules are benign [2, 3]. In 5% of fine-needle 
aspiration biopsies a thyroid cancer is diagnosed [4, 
5]. Standard pre-operative diagnostic tests of nodular 
goitre are mainly based on two investigations: a thyroid 
ultrasound (US) and ultrasound-guided fine-needle 
aspiration biopsy (US-FNAB). A thyroid FNAB remains 
the most sensitive and the most specific pre-operative 
diagnostic test for thyroid cancer. However, its results 
may not always be conclusive. Patients with non-diag-
nostic results in two consecutive thyroid FNABs and 
some patients with indeterminate follicular lesions are 
candidates for thyroid surgery, although only 10–20% 
of these tumours turn out to be cancerous [4, 5].
Patients with nodular goitre who initially have not 
been selected for surgery still require periodic US and 
cytology monitoring of their focal lesions in the thyroid 
gland. Even though these standard investigations may 
be performed on a regular basis, they do not always 
provide sufficient information on the risk of neoplastic 
transformation in the so-far benign thyroid nodules. 
The selection of patients for nodular goitre surgery is 
more and more commonly based on molecular methods 
evaluating the frequency of mutations in the selected 
genes and epigenetic changes involved in the neoplastic 
transformation processes [6].
The aim of this study was to determine BRAF 
T1799A mutation and KRas proto-oncogene mutation as 
well as the analysis of RASSF1A promoter methylation 
levels in the cytological material obtained from nodular 
goitres using fine-needle aspiration biopsy. 
The authors made an attempt to assess the value of 
selected molecular methods for pre-operative diagnosis 
of nodular goitre.
Material and methods
Ninety-seven (97) patients with nodular goitre were 
included in the study. Hyper- and hypothyroidism were 
excluded with hormone testing, while the presence of 
autoimmune chronic inflammatory process involving 
the thyroid gland was ruled out with antithyroid an-
tibody tests and a thyroid ultrasound. The following 
investigations were performed for each patient:
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all PCR conditions, this fragment was amplified in Veriti 
96 Well Fast Thermal Cycler (Applied Biosystems) with 
60 μL of reaction mixture containing the following 
components: 
 — 12 μL bisulphite-treated DNA 
 — 30 μL 2XPCR Master Mix (MBI Fermentas)
 — 3 μL PCR Primer Set [10×] — primer reverse with 
5’-biotin modification (PyroMark CpG Assay — 
Hs_RASSF1_03_PM; QIAGEN)
 — 3 μL PCR Primer Set [10×] — starter reverse with 
5’-biotin modification (QIAGEN)
 — 15 μL H2O
The following temperature and time profiles were ap-
plied in PCR:
Phase I: preliminary denaturation 95˚C — 15 min.
Phase II (50 cycles):
 — denaturation: 95˚C — 20 sec.
 — hybridization: 56˚C — 40 sec. 
 — elongation: 72˚C — 40 sec.
Phase III: final elongation 72˚C — 10 min.
The quality of the PCR product obtained was veri-
fied during electrophoresis in 2% agarose gel stained 
with ethidium bromide. In order to do that, 8 μL of PCR 
product with the addition of 2 μL of bromophenol blue 
was applied to the gel. The separation was performed 
in 1xTBE buffer [0.089 M Tris, 0.089 M boric acid, 2 mM 
EDTA], at 20˚C and a voltage of 75 V. The length of PCR 
product was determined with DNA size marker — pUC 
Mix Marker 8 (MBI Fermentas). The final stage was to 
take photographs documenting the gel using Polaroid 
DS-34 Direct Screen Camera, in UV light (Transilumina-
tor 4000, Stratagene).
Immobilization of biotinylated PCR product onto 
streptavidin
80 μL of reaction mixture was applied on a 96-well PCR 
plate. The reaction mixture consisted of:
 — 37 μL of PCR product
 — 3 μL of streptavidin–coated sepharose beads 
 — 40 μL of PyroMark Binding Buffer (QIAGEN)
The plate was foil-wrapped and placed in a thermo-
mixer (800 rpm, room temperature) for 10 minutes.
Preparing PyroMark Q96 HS Plate
12 ml of the mixture was dispensed into a PyroMark 
Q96 HS Plate. The mixture consisted of:
 — 1.2 μL Sequencing Primer [10×] (PyroMark CpG 
Assay - Hs_ RASSF1_03_PM; QIAGEN)
 — 10.8 μL PyroMark Annealing Buffer (QIAGEN)
Then, both plates (PyroMark Q96 HS Plate and 
PCR plate) were placed in a PyroMark Q96 Vacuum 
Workstation. After gentle aspiration of PCR products, 
the filters were flushed sequentially in 70% ethanol 
(10 sec.), Denaturation Solution (10 sec.), and Wash 
Buffer (10 sec.). Once the flushing had been completed, 
the filters were immersed in a PyroMark Q96 HS Plate 
and then the plate was wrapped in aluminium foil and 
placed in a PyroMarkQ HS Sample Prep Thermoplate 
in the incubator at 80˚C. Plate incubation at 80˚C lasted 
for 10 minutes. The plate was left undisturbed for 
30 minutes to cool down to room temperature.
Analysis with a Pyromark MD pyrosequencer 
(Biotage)
After cooling down to room temperature, the Pyro-
Mark Q96 HS Plate was loaded onto a Pyromark MD 
pyrosequencer (Biotage) to perform a pyrosequencing 
reaction. Pyrosequencing was performed with the 
reagents included in a PyroMark Q96 Gold Reagents 
kit (QIAGEN). The resultant sequential pyrograms (Fig. 
1) were analysed with Pyro Q-CpG Software (Biotage).
Detecting KRas mutation
Mutations at KRas codons 12 and 13 (exon 2) and 61 
(exon 3) were determined (Table I). 
The mutations were detected using Sanger se-
quencing method with direct sequence identification 
in a capillary analyser. Two pairs of starters anchored 
Figure 1. Example of a sequential pyrogram obtained for RASSF1 gene 
Rycina 1. Przykładowy pirogram sekwencyjny genu RASSF1 
387
Endokrynologia Polska 2015; 66 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
outside the sequenced exon region were used for each 
sequenced exon 2 and exon 3. One of the starter pairs 
used for the sequencing of each exon allowed for 
the amplification of short DNA fragments (less than 
200 base pairs), so that the identification of mutations 
was possible even for partially degraded genetic mate-
rial. Starter sequences used for amplification are listed 
in Table II; standard M13 starters (M13 F 5’ TGTAAAAC-
GACGGCCAGT 3’, M13 R 5’ CAGGAAACAGCTATGACC 
3’) were used for sequencing. 
At least 20 ng of genomic DNA was used for am-
plification, in the conditions described below, using 
AmpliTaq Gold polymerase on an ABI 9700 thermocy-
cler (Applied Biosystems, USA). Once the amplification 
products had been purified (ExoSAP enzyme), the se-
quencing reaction was prepared (see the conditions be-
low) using standard M13 starters; each sequencing was 
performed in two directions (forward and reverse). After 
the sequencing reaction and purification of the products 
with BigDye XTerminator enzyme (Applied Biosystems, 
USA), product separation and detection with capillary 
electrophoresis were performed, and consequently, typi-
cal chromatograms were obtained. ABI 3500 (4-capillary) 
sequencer was used for electrophoresis.
Reaction conditions:
Amplification:
 — reagents
• AmpliTaq Gold® PCR Master Mix 25 μL
• Starer 1 (A/C/E/G) (5 pM) 5 μL
• Starter 2 (B/D/F/H) (5 pM) 5 μL
• genomic DNA (minimum 20 ng)
• H2O to obtain the volume of 50 μL 
 — reaction conditions
Phase I: preliminary denaturation 96°C — 5 min.
Phase II (35 cycles):
 — denaturation: 94°C — 30 sec.
 — annealing: 58°C — 45 sec.
 — elongation: 72°C — 45 sec.
Phase III: final elongation 72°C — 10 min.
Sequencing: 
 — reagents:
BigDye® Terminator Cycle Sequencing Kit v3.1 Master 
Mix 4 μL
starter M13 (0.8 pmol/μL) 4 μL
buffer 5X 2 μL
purified amplification product: (10 ng)
H2O to obtain the volume of 20 μL
 — reaction conditions: 
Phase I: preliminary denaturation: 96°C — 1 min.
Phase II (25 cycles): 
 — denaturation: 96°C — 10 sec.
 — annealing: 50°C — 5 sec.
 — elongation: 60°C — 2 min.
Phase III: final elongation 72°C — 10 min.
The assembly of sequences based on the obtained 
chromatograms was performed with Recall on-line tool 
(http://pssm.cfenet.ubc.ca/home/show) (Fig. 2) and ref-
erence sequences for exon 2 (ATGACTGAATATAAACTT-
GTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAG
TGCCTTGACGATACTCGAAATTCAGAATCATTTT-
GTGGACGAATATGATCCAACAATAGAG) and exon 3 
(GATTCCTACAGGAAGCAAGTAGTAATTGATGGAGA-
AACCTGTCTCTTGGA
TATTCTCGACACAGCAGGTCAAGAGGAGTACAGTG-
CAATGAGGGACCAGT
ACATGAGGACTGGGGAGGGCTTTCTTTGTGTATTT-
GCCATAAATAATACT
AAATCATTTGAAGATATTCACCATTATAGG). 
Identifying BRAF mutation
BRAF mutation was identified with standard methods 
for the real-time fluorescence detection of amplifica-
Table I. KRas codons and mutations detected with sequencing 
method
Tabela I. Kodony i mutacje KRas wykrywane metodą 
sekwencjonowania
Gly12Asp (GGT > GAT)
Gly12Val (GGT > GTT)
Gly12Cys (GGT > TGT)
Gly12Ser (GGT > AGT)
Gly12Ala (GGT > GCT)
Gly12Arg (GGT > CGT)
Gly13Asp (GGC > GAC)
Gln61Leu (CAA > CTA)
Table II. Starter sequence for KRas amplification
Tabela II. Sekwencja starterów do ampilfikacji KRas
Starter sequence*
A 5’ tgtaaaacgacggccagtTATTTGATAGTGTATTAACCTTATGTGTG 3’
B 5’ caggaaacagctatgaccGAAACCTTTATCTGTATCAAAGAATG 3’
C 5’ tgtaaaacgacggccagt TGTGACATGTTCTAATATAGTCACATT 3’
D 5’ caggaaacagctatgacc ACCAGTAATATGCATATTAAAACAAGA 3’
E 5’ tgtaaaacgacggccagtAGGTGCACTGTAATAATCCAGA 3’
F 5’ caggaaacagctatgaccCTATAATTACTCCTTAATGTCAGCTTATT 3’
G 5’ tgtaaaacgacggccagt GACTGTGTTTCTCCCTTCTCA 3’
H 5’ caggaaacagctatgacc AGCTTATTATATTCAATTTAAACCCAC 3’
*lower-case letters used to denote a sequence complementary to M13 
starters; upper-case letters used for KRAS exons. A-D starters: exon 2, E-H 
starters: exon 3.
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Figure 2. A sample chromatogram fragment obtained for KRas exon 2 (Recall on-line tool)
Rycina 2. Przykładowy fragment chromatogramu dla egzonu 2 KRas (Recall on-line tool)
tion (real-time PCR) using specific starters surrounding 
the mutated site. For each sample, separate reactions 
were performed with BRAF mutation-specific probe 
and the probe specific for the absence of BRAF muta-
tion. TaqMan Mutation Detection Assay kit (Applied 
Biosystems, the USA) was used for the detection, 
with BRAF_475_mu and BRAF_476_mu reagents 
as well as specific reagents detecting non-mutated 
sequences. The amplification was performed us-
ing a StepOne system (Applied Biosystems, Foster 
City, CA, USA) at standard conditions of the reac-
tion. The final volume of reaction mixture (20 μl) 
for each reaction contained 20 ng of genomic DNA, 
900 nM of each starter, 300 nM of each probe, and 
10 μl of Genotyping Master Mix (Applied Biosys-
tems, Foster City, CA, USA). Reaction conditions: 
Preliminary activation: 10 min. at 95˚C followed by 
40 amplification cycles (denaturation at 95˚C for 
15 seconds and annealing /elongation at 60˚C for 
1 min. with the acquisition of fluorescence signal). 
The direct result — the presence or absence of muta-
tion in a given sample — was based on the presence of 
fluorescence signal. 
Statistical analysis
Since distributions of most quantitative variables 
were significantly different from normal distribution 
(Shapiro-Wilk test, p < 0.05), we used non-parametric 
Mann-Whitney test to compare values between groups, 
and Spearman rank correlation coefficient to analyse 
correlations between parameters. The general linear 
model (GLM) was used to find independent factors 
associated with methylation. Variables with right-skewed 
distributions (mean methylation, tumour volume, and 
maximal diameter) were transformed logarithmically 
before inclusion into the model. P < 0.05 was considered 
statistically significant. Statistica 10 software was used 
for calculations.
Results
Study population characteristics
The study group consisted of 97 subjects, including 
85 women (87.6%) and 12 men (12.4%). Mean age of 
study subjects was 51 ± 12.2 years (median age: 54; 
range: 21–69 years). 
Thyroid ultrasound findings
Mean thyroid volume in the study population was 
16.5 mL (median volume: 14.25 mL range: 4.6–51 mL). 
The volume of each biopsied thyroid nodule was 
calculated using spheroid volume formula: volume 
[mL] = width [cm] × depth [cm] × length [cm] × π/6. 
Mean tumour volume was 1.8 mL (median volume: 
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0.624 mL; range: 0.06–26.25 mL). The analysis of the 
maximum diameter of the biopsied nodules yielded 
the mean value of 16.1 mm (median value: 14 mm; 
range: 2–60 mm). In 21.6% (21/97) of patients, one focal 
lesion was found in the thyroid gland; 38.2% (37/97) of 
study subjects had two focal lesions, while three and 
more lesions were found in 40.2% (39/97) of patients. 
Fine-needle aspiration biopsy was performed on 
97 focal lesions, including 68 solid focal lesions (70.1%), 
26 mixed solid and fluid-filled focal lesions (26.8%), and 
3 fluid-filled focal lesions (3.1%). The analysis of nodule 
echogenicity showed that the lesions with reduced 
echogenicity were predominant (47.4%), while 44.3% 
of lesions were normoechogenic, and there were 6.2% 
lesions with non-homogenous echogenicity and 2.1% 
hyperechogenic lesions. A halo was not observed in 
93.8% of focal lesions. Micro-calcifications were found 
in 12.4% of focal lesions, and macro-calcifications were 
seen in 14.5% of lesions.
Thyroid FNAB findings
The cytology findings of thyroid nodules included: be-
nign lesions in 83.5% (81/97) of subjects (group II), non-
diagnostic material in 14.4% (14/97) of subjects (group 
I), indeterminate follicular lesion in one patient (group 
III), and a lesion suspicious for follicular neoplasm in 
one patient (group IV). Out of the whole group of 
97 patients, five underwent thyroid surgery. Histologi-
cal pathology report showed a papillary thyroid cancer 
(PTC) in three of these patients (3.1%) and a benign 
lesion in the remaining two subjects. Among patients 
with the diagnosis of papillary thyroid cancer, two had 
non-diagnostic cytology material. These patients were 
selected for surgery because of sonographic features 
of the focal lesions in the thyroid gland. In one person 
with papillary thyroid cancer, a cytology report of 
indeterminate follicular lesions was obtained.
Molecular tests
RASSF1A gene methylation 
Mean methylation levels of four CpG islands included 
in the analysis and the methylation of each individual 
CpG island of RASSF1A gene in cytology specimens of 
thyroid nodules are presented in Table III.
Mean methylation levels and the methylation of 
each individual CpG island of RASSF1A gene in cyto-
logy specimens of thyroid nodules in patients with PTC 
diagnosed in histopathology material are presented in 
Table IV.
The tests showed a significant positive correlation 
between mean methylation level of four CpG islands 
in RASSF1A gene and the volume of thyroid tumour as 
well as the largest tumour diameter (p < 0.05). Table V 
presents mean methylation levels of four CpG islands 
of RASSF1A gene in three groups distinguished by 
the largest tumour diameter (< 10 mm, 10–20 mm, 
≥ 20 mm). No statistically significant correlation was 
found between mean methylation levels of four CpG 
islands and subjects’ age, sex, the number of thyroid nod-
ules ≤ 2, and the volume of the thyroid gland. A negative 
correlation was observed between mean methylation 
level and the number of thyroid nodules exceeding two 
(the result was at the border-line of statistical signifi-
cance, p = 0.054). There was a statistically significant, 
positive correlation between mean methylation level 
and the presence of a mixed solid and fluid-filled focal 
lesion. No correlation was found between mean methy-
lation level of analysed CpG islands and the presence 
Table III. Mean methylation levels and the methylation of 
individual CpG islands of RASSF1A gene in the cytology 
specimens of thyroid nodules
Tabela III. Odsetek średniej metylacji i metylacji 
poszczególnych wysp CpG genu RASSF1A w materiale 
cytologicznym guzków tarczycy
n Mean ± SD  
(%)
Median (range)  
(%)
Mean methylation 97 10.3 ± 4.6 9.75 (2.25–23.75)
Methylation of 1CpG 97 11.0 ± 6.2 10 (2–33)
Methylation of 2CpG 97 6.7 ± 3.2 6 (2–17)
Methylation of 3CpG 97 16.7 ± 10.1 15 (2–53)
Methylation of 4CpG 97 6.5 ± 4.9 6 (2–44)
Table IV. Mean methylation levels and the methylation of individual CpG islands of RASSF1A gene in the cytology specimens 
of thyroid nodules sampled from patients with histopathology-diagnosed papillary thyroid carcinoma
Tabela IV. Odsetek średniej metylacji i metylacji poszczególnych wysp CpG genu RASSF1A w materiale cytologicznym guzków 
tarczycy u pacjentów z rakiem brodawkowatym rozpoznanym w materiale histopatologicznym
No. Sex AGE 
(years)
Mean methylation 
(%)
Methylation 
of 1CpG (%)
Methylation 
of 2 CpG (%)
Methylation  
of 3CpG (%)
Methylation 
of 4CpG (%)
1 F 66 4 8 2 3 2
2 F 62 9 10 6 15 5
3 F 48 11 12 7 20 6
390
PR
A
C
E 
O
RY
G
IN
A
LN
E
BRAF, KRas, RASSF1A in nodular goiter  Monika Koziołek et al.
of a solid or fluid-filled focal lesion; likewise, there was 
no correlation between mean methylation level and 
lesion echogenicity. 
Multifactorial models including subjects’ age and 
sex as well as the presence of more than two nodules 
and logarithmic nodule size (given as the volume and 
the largest diameter of the nodule) showed that larger 
and fewer (< 2) nodules are independent factors as-
sociated with higher (logarithmic) methylation levels 
of CpG islands. 
KRas gene mutation
KRas mutations were investigated in DNA of cytology 
specimens sampled from thyroid nodules of 97 patients, 
and no such mutations were found.
BRAF gene mutation
The investigations of BRAF mutations in DNA of 
thyroid nodule cells were carried out in 85 subjects 
(in 12 patients, the amount of DNA was insufficient 
to obtain reliable results). In seven subjects (8.2%), 
BRAF mutation was found in cytology material and, 
consequently, peripheral blood DNA was investigated 
in these patients, and BRAF mutation was found in one 
of them. Mean methylation levels of four analysed CpG 
islands and the methylation of each island separately, 
the characteristics of the biopsied focal lesions in the 
thyroid gland and cytology findings in patients with 
BRAF mutation are presented in Table VI. In six patients 
with BRAF mutation, the FNAB findings in the thyroid 
nodules included benign lesions, and in one subject 
non-diagnostic material was reported. The latter pa-
tient underwent thyroid surgery, and papillary thyroid 
cancer was diagnosed based on histological pathology.
Discussion
Ultrasound-guided fine-needle aspiration biopsy is 
currently the best method used in the diagnosis of thy-
roid nodules. However, the results of studies show that 
in 10–20% of biopsies the sampled material is insuf-
ficient to establish the diagnosis and approx. 20% thy-
roid nodule biopsies require additional histopathologi-
cal assessment of post-operative material to establish 
a final diagnosis [4, 7, 8]. The FNAB findings may 
be non-diagnostic because of insufficient follicular 
cellularity, poor fixation, or poor preservation of the 
material.
The value of FNAB in the pre-operative diagnosis 
of nodular goitre may increase significantly when mo-
lecular DNA tests of cytology material obtained from 
biopsied thyroid nodules are included in the standard 
cytology diagnosis. 
Ras proto-oncogene mutations and BRAF gene mu-
tations, as well as aberrant DNA methylation in the 
regions of promoter genes regulating the cell cycle, 
play an important role in the initiation of the neoplastic 
transformation of thyrocytes. 
The most common BRAF gene mutation observed in 
the papillary thyroid carcinoma (40–70% of PTC cases) is 
the thymidine to adenine transversion at position 1799 
(T1799A) in exon 15 of the BRAF gene, resulting in the 
valine (V) to glutamic acid (E) substitution at residue 
600 (V600E) [9–15]. Many studies demonstrate that this 
mutation is observed mainly in papillary thyroid carci-
noma and in 25% of anaplastic thyroid cancers [15–17]. 
T1799A BRAF oncogene is found at all stages of PTC 
progression; it is detected even in the early stages of its 
development [15, 18–20]. 
In our study, BRAF mutations were observed in 8.2% 
of analysed subjects (7/85) in FNAB cytology specimens 
of thyroid nodules. In 6/7 subjects with T1799A BRAF 
mutation, FNAB findings showed that the lesions were 
benign, while in one female patient the specimen was 
non-diagnostic. This woman was ultimately diagnosed 
with papillary thyroid carcinoma based on histopathol-
ogy assessment of postoperative material.
In a study conducted by Zhang B. et al., BRAF mu-
tation was present in cytology material obtained from 
30 out of 42 (71.43%) thyroid nodules with papillary 
thyroid carcinoma, while this mutation was not detect-
ed in any of the patients with benign lesions confirmed 
with biopsy [4]. On the other hand, Xing M. et al. [14] 
investigated BRAF mutation in the FNA-biopsied thy-
roid nodules of 40 patients and in the postoperative 
thyroid tissue specimens. Histopathology findings 
included: papillary thyroid carcinoma (16 patients), 
follicular thyroid carcinoma (five patients), Hurthle 
cell carcinoma (one patient), adenoma or hyperplasia 
(14 patients), metastatic clear cell renal cell carcinoma 
(one patient), Graves’ disease (one patient), Hashimoto’s 
disease (one patient), and amiodarone-induced thy-
rotoxicosis (one patient). The analysis of these results 
Table V. Mean methylation levels of four CpG islands of 
RASSF1A gene in three subgroups by tumour size
Tabela V. Odsetek średniej metylacji czterech wysp CpG genu 
RASSF1A w trzech grupach utworzonych w zależności od 
wielkości guzka
n Mean ± SD
Median 
(range)
Mean methylation level (%) in 
tumours < 10 mm
20 9.15 ± 4.2 8.3 (2.25–16.75)
Mean methylation level (%) in 
tumours 10 mm to < 20 mm
51 9.4 ± 4.3 8.75 (2.25–21)
Mean methylation level (%) in 
tumours ≥ 20 mm
26 12.8 ± 4.7 12.25 (6–23.75)
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showed that BRAF mutation was present in 50% of 
nodule specimens obtained from pre-operative fine-
needle biopsy (8/16) which turned out to be papillary 
thyroid cancer in post-operative histopathology. On 
the other hand, BRAF mutation was not detected in 
any other samples for which different histopathology 
diagnoses were established. In addition, BRAF muta-
tion was detected in cytology specimens sampled from 
two patients with indeterminate FNAB results, and 
final histopathology findings supported the diagnosis 
of papillary thyroid carcinoma, just as it was the case 
in our material. 
There are many reports dedicated to genetic tests 
on FNAB cytology specimens, focusing mainly on non-
diagnostic material, indeterminate follicular lesions, 
and the lesions suspected of follicular neoplasm [1, 4, 
5, 8, 14, 21]. The presence of BRAF mutation in a FNAB 
cytology specimen of thyroid nodule is an indication 
for nodular goitre surgery. It should be remembered, 
however, that there are 0.2–5.7% of false positive BRAF 
T1799A results in the nodule and 1.9–5.8% of false nega-
tive results [22, 23]. A negative BRAF mutation result 
in the thyroid nodule may be the consequence of an 
insufficient number of cells with mutated BRAF genes 
in some FNAB cytology specimens. At present, there 
are reasons to repeat FNAB BRAF mutation test after 
6–12 months, particularly when suspicious sonographic 
features are observed and cytology findings are non-
diagnostic or signs of atypia are detected [24].
Jia Y. et al. conducted a meta-analysis of literature 
data demonstrating that the BRAF mutation test was a 
valuable adjunctive diagnostic tool in the assessment 
of nodules that are difficult to evaluate with currently 
available methods [1]. Koh J. et al., on the other hand, 
analysed the indications for BRAF mutation tests ad-
ditional to cytology in the diagnosis of nodular goitre, 
confirming the value of these tests in pre-operative 
assessment of thyroid nodules with suspicious sono-
graphic features [21]. Rossi M. et al. demonstrated that 
BRAF mutation tests in FNAB cell specimens enhance 
the diagnostic sensitivity of cytology by 28% (p < 0.01) 
in the diagnosis of thyroid cancer [25].
As in traditional cytological assessment, the analysis 
of genetic mutation in cytology specimens may be dif-
ficult because of insufficient cellularity, despite the use 
of genomic DNA amplification techniques. This was 
also observed in some of our cases.
Ras mutations are detected in both benign and ma-
lignant thyroid neoplasms, more frequently in follicular 
cancers (< 50%) than in papillary cancers (5–20%), 
but literature reports are greatly inconsistent on the 
incidence of these mutations, particularly in adenomas 
(in general < 30%) [9, 10, 26, 27]. A follicular adenoma 
with Ras mutation may be a precursor of both follicular 
cancer and a follicular variant of papillary carcinoma. 
Recent studies indicate that Ras mutation is a valuable 
diagnostic marker in nodules in which the diagnosis 
cannot be established on the basis of FNAB cytology 
Table VI. Mean methylation of 4 CpG islands of RASSF1A gene and the methylation of each individual island, the characteristics 
of biopsied focal lesions in the thyroid gland, and cytology findings in patients with BRAF mutation
Tabela VI. Średnia metylacji 4 badanych wysp CpG genu RASSF1A i metylacja każdej z tych wysp, charakterystyka 
bioptowanych zmian ogniskowych w tarczycy oraz ich wynik cytologiczny u pacjentów z obecnością mutacji genu BRAF
No. Sex Age 
(years)
Greatest 
diameter 
of tumor 
[mm]
Tumor 
structure
Tumor 
echogenicity
Halo Micro-
calcifications
Mean 
methylation 
(%)
1 CpG 
(%)
2 CpG 
(%)
3 CpG 
(%)
4 CpG 
(%)
Cytology  
findings
Histopathology 
findings **
1 F 68 6 Mixed solid 
and fluid-
filled
Normoecho-
genic
– – 5 4 5 6 5 Group II
2 F 63 10 Solid Hypoechogenic – + 7 6 9 7 7 Group II
3 F 66 15 Solid Normoecho-
genic
+ – 4 8 2 3 2 Group I PTC
4 M 45 10 Solid Normoecho-
genic
– – 11 5 4 30 4 Group II
5 F 53 19 Mixed solid 
and fluid-
filled
Normoecho-
genic
– – 13 15 7 24 8 Group II
6 F 22 20 Mixed solid 
and fluid-
filled
Normoecho-
genic
+ + 7 4 3 15 4 Group II Benign lesion
7* F 41 8 Solid Hypoechogenic – – 9 4 4 24 3 Group II
*No. 7: additionally, BRAF mutation was detected in peripheral blood DNA; **To date, thyroid surgery has been performed in 2 out of 7 these 7 subjects
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specimens, particularly in follicular variant of papil-
lary carcinoma as well as in follicular carcinoma and 
adenoma [6,28]. 
This problem has been investigated by Lee S.R. et al., 
who analysed 59 historical FNAB reports with histologi-
cal pathology diagnosis of follicular variant of papillary 
carcinoma. FNAB cytology findings in these patients 
included: a benign lesion in 5% of subjects, atypic cells 
in 19% of subjects, a follicular neoplasm or suspected 
follicular neoplasm in 14% of subjects, a suspected 
papillary cancer in 29% of patients, and a papillary 
cancer in 34% of patients. In the above-quoted study, 
the mutations of three Ras proto-oncogenes in FNAB 
cytology specimens were observed in 18 (33%) nodules, 
including NRas in 22%, HRas in 6%, and KRas in 6% of 
Ras-positive nodules. Lee S.R. et al. showed Ras muta-
tion in 67%, 56%, and 63% of biopsies with the following 
cytology findings: a benign lesion, atypia/indeterminate 
follicular lesion, and a follicular neoplasm, respectively. 
The mutations of three Ras genes were found in codon 
61, while they were not observed in codons 12 and 
13. Lee S.R. et al. concluded that the investigations 
of Ras proto-oncogene mutations were useful for the 
improvement of sensitivity in false-negative cytology 
material, although these authors do not recommend 
Ras mutational analysis in all patients with cytology 
reports of benign thyroid nodules [29]. 
Out of the three Ras proto-oncogenes (NRas, HRas, 
and KRas), the most common mutation is the one in 
NRas and HRas codon 61. Mutations in codons 12 and 
13 of KRas gene are much less common, which has been 
confirmed by Lee S.R. et al. [29–31]. We investigated 
mutations in codons 12, 13, and 61 of KRas gene in the 
DNA of cytology specimens of thyroid nodules sampled 
from 97 subjects — no mutation was detected in any of 
the subjects. Although our findings are different from 
those obtained by Lee S.R. et al., we made similar con-
clusions regarding the value of KRas proto-oncogene 
mutational analysis in the cytology-diagnosed benign 
lesions. 
The role of epigenetic mechanisms in neoplastic 
transformation of the thyroid gland has also been dis-
cussed in recent years. Epigenetic silencing of suppres-
sor gene RASSF1A through promoter hypermethylation 
may lead to the loss of control of thyroid cell differentia-
tion and proliferation. RASSF1A gene hypermethyla-
tion is observed both in benign and malignant thyroid 
neoplasms, and it is particularly frequent in follicular 
cancer [32, 33]. 
In our study, we did not find any association be-
tween mean methylation levels of four CpG islands and 
patients’ age, sex, the number of nodules ≤ 2, thyroid 
volume, or the echogenicity and structure of a focal 
lesion (solid and fluid-filled). Although the possibly 
cancerous nature of a thyroid nodule is indicated by 
sonographic features of nodule malignancy such as 
nodule echogenicity, structure, the presence of micro-
calcifications or irregular contours rather than its size, 
larger size of the nodule is associated with higher risk 
of malignant transformation. We demonstrated that 
mean methylation levels of four analysed CpG islands 
in RASSF1A gene correlated positively with the volume 
of the nodule and its largest diameter, which may be 
significant for neoplastic transformation of the so-far 
benign focal lesion in the thyroid gland. No information 
has been found in the available literature on the associa-
tion between RASSF1A methylation level in cytology 
specimens of thyroid nodules and their sonographic 
characteristics. Most published studies on RASSF1A 
methylation analyse thyroid tissue specimens obtained 
from surgical samples [33–35]. 
In a study of thyroid tissues obtained from surgical 
samples, Hing M. et al. found that 44% of benign adeno-
mas, 75% of follicular thyroid cancer tumours, and 20% 
of papillary thyroid cancer tumours showed promoter 
methylation in more than 25% of RASSF1A alleles [33]. 
An interesting report has been published by Kunstman 
et al., who analysed RASSF1A methylation in thyroid 
tissues obtained during surgery from 41 patients with 
PTC and from 18 patients without thyroid pathology. 
These authors also analysed the correlation between 
RASSF1A methylation in patients with PTC and disease 
progression (lymph node metastases, extracapsular 
invasion), multifocality of the cancer, and PTC variant 
(classic, follicular, tall cell PTC). Kunstman et al. found 
that mean methylation was 4.2 times greater in PTC 
than in normal thyroid tissue (p < 0.05) and mean 
methylation was higher in multifocal than unifocal 
PTC (p < 0.05) [36].
In the study by Zhang B. et al. quoted above, 
along with BRAF mutation in thyroid nodule FNAB 
cytology specimens, the authors also investigated the 
methylation of five selected genes, including RASSF1A. 
They found significantly lower RASSF1A methylation 
levels in PTC than in benign lesions (p = 0.003) and 
an inverse correlation between BRAF mutation and 
RASSF1A methylation [4]. Similarly, a female patient 
with confirmed PTC and BRAF mutation included in 
our study displayed the lowest mean methylation levels 
of four CpG islands (Table VI). Zhang B et al. suggest 
that the study of suppressor gene methylation in FNAB 
cell specimens of thyroid nodules has considerable 
restrictions, but the authors still believe that combined 
testing of BRAF mutation and DNA methylation in 
selected genes would enhance the diagnostic value of 
pre-operative assessment of nodular goitre [4].
Since the role of epigenetic mechanisms in the de-
velopment of thyroid cancer has been documented and 
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RASSF1A methylation can be detected at an early stage 
of carcinogenesis, further epigenetic studies of FNAB 
cell specimens of thyroid nodules are necessary. These 
studies will improve the diagnostic accuracy of thyroid 
nodules, and in cases of suppressor gene promoter 
methylation, they will be helpful in making a decision 
about total thyroidectomy in order to avoid two-stage 
surgery, which increases the number of post-operative 
complications and the costs of treatment. 
Conclusions
The results of genetic tests reported in our study in-
dicate that the presence of BRAF mutation or higher 
RASSF1A methylation level in FNAB cytology speci-
mens of benign lesions may be useful in the assess-
ment of oncological risk, while the evaluation of KRas 
proto-oncogene mutation is not a valuable test in pre-
operative diagnosis of nodular goitre. 
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